|Brand Name:||Aeronid (HFA)|
|Weight:||200 mcg/metered inhalation|
|Therapeutic Class:||Nasal Decongestants & Other Nasal Preparations, Respiratory corticosteroids|
|Manufacturer:||Beximco Pharmaceuticals Ltd.|
|Last Updated:||2020-11-22 18:15:00|
Aeronid (HFA) Inhaler contains Budesonide. Aeronid (HFA) uses:
Budesonide is a glucocorticoid indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis.
Budesonide Nebuliser suspension is indicated for the maintenance treatment and as prophylactic therapy of asthma.
Budesonide Nasal Spray is indicated for-
Budesonide Inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy in adult and paediatric patients six years of age or older. It is also indicated for patients requiring oral corticosteroid therapy for asthma, many of those patients may be able to reduce or eliminate their requirement for oral corticosteroids over time. Budesonide inhaler is not indicated for the relief of acute bronchospasm.
Aeronid (HFA) Inhaler contains Budesonide 200 mcg/metered inhalation. Aeronid (HFA) doses:
Children 3 months to 12 years of age: 0.5 - 1 mg twice daily.Adults and elderly: 1 - 2 mg twice daily.
●headache● nausea● upper abdominal pain● fatigue● acne● flatulence● joint pain● urinary tract infection● abdominal distension● constipation
Budesonide is a synthetic corticosteroid having potent glucocorticoid activity and weak mineralocorticoid activity. It has approximately a 200-fold higher affinity for the glucocorticoid receptor and a 1000-fold higher topical anti-inflammatory potency than cortisol. Corticosteroids have been shown to have a wide range of inhibitory activities against multiple cell types (e.g., mast cell, eosinophil, neutrophil, macrophage, and lymphocyte) and mediators (e.g., histamine, eicosanoids, leukotriene, and cytokine) involved in allergic mediated inflammation.
● Since budesonide is a glucocorticoid, general warnings concerning glucocorticoids should be followed.
● Risk of impaired adrenal function when transferring from glucocorticoid treatment with higher systemiceffects to glucocorticoid treatment with lower systemic effects, such as budesonide. Taper patients slowly fromsystemic corticosteroids if transferring to budesonide.
● Potential worsening of infections (e.g., chickenpox, measles, existing tuberculosis, fungal, bacterial, viral, orparasitic infection). Use with caution in patients with these infections.
● Reduced liver function affects the elimination of glucocorticoid, and increases systemic availability of oralbudesonide.
Avoid Cytochrome P450 3A4 inhibitors (e.g. ketoconazole, grapefruit juice). It may cause increased systemic corticosteroid effects. Budesonide does not affect the plasma levels of oral contraceptives.
Pregnancy Category CThere are no adequate and well-controlled studies in pregnant women. Budesonide should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Nursing mothers
Budesonide is secreted in human milk. So, a decision should be made whether to discontinue nursing or budesonide taking into account the clinical importance of the drug to the mother.
Use in childrenSafety and effectiveness of budesonide in pediatric patients have not been established.Use in Hepatic Impaired patientsMonitor patients for signs and/or symptoms of hypercorticism.
Hypersensitivity to any of the ingredients of this preparation.
If glucocorticoids are used at excessive doses for prolonged periods, systemic glucocorticoid effects such as hypercorticism and adrenal suppression may occur.
Symptoms: Decreased motor activity, piloerection, generalised oedema. Management: Immediate gastric lavage or emesis followed by supportive and symptomatic treatment.
Aeronid (HFA) Inhaler price in Bangladesh 574.00